In addition to being used alone or in combination with other oral agents, pioglitazone is also licensed (EMEA 2008)[8] for use in combination with insulin in type 2 diabetes patients with insufficient glycaemic control on insulin, and for whom metformin is inappropriate because of contraindications or intolerance. Here, INS is linked to type 2 diabetes mellitus.